Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Valion Bio (TIVC) Inventory (2021 - 2025)

Valion Bio has reported Inventory over the past 5 years, most recently at $572000.0 for Q3 2025.

  • For Q3 2025, Inventory fell 21.75% year-over-year to $572000.0; the TTM value through Sep 2025 reached $572000.0, down 21.75%, while the annual FY2024 figure was $657000.0, 16.62% down from the prior year.
  • Inventory for Q3 2025 was $572000.0 at Valion Bio, down from $621000.0 in the prior quarter.
  • Over five years, Inventory peaked at $988000.0 in Q2 2023 and troughed at $429000.0 in Q4 2021.
  • A 5-year average of $738312.5 and a median of $774500.0 in 2022 define the central range for Inventory.
  • Biggest five-year swings in Inventory: surged 110.96% in 2023 and later decreased 22.95% in 2025.
  • Year by year, Inventory stood at $429000.0 in 2021, then soared by 101.17% to $863000.0 in 2022, then fell by 8.69% to $788000.0 in 2023, then decreased by 16.62% to $657000.0 in 2024, then fell by 12.94% to $572000.0 in 2025.
  • Business Quant data shows Inventory for TIVC at $572000.0 in Q3 2025, $621000.0 in Q2 2025, and $644000.0 in Q1 2025.